Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Smoking and body weight influence the clearance of chlorpromazine.

Literature DB >> 7995319

Smoking and body weight influence the clearance of chlorpromazine.

Abstract

The population pharmacokinetic parameters of chlorpromazine (CPZ) in chronic schizophrenic patients were evaluated using 189 plasma concentration measurements from 31 patients. A NONMEM analysis demonstrated that the clearance of CPZ depended on the patient's body weight. Cigarette smoking and cannabis smoking increased the clearance of CPZ. Chronic alcohol consumption and the concurrent use of anticholinergics did not appear to influence the clearance of CPZ significantly.

Entities: Chemical Disease Species

Mesh：

Substances：
Ethanol
Chlorpromazine

Year: 1994 PMID： 7995319 DOI： 10.1007/BF00196109

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

17 in total

1. Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics.

Authors: L Rockland; T Cooper; F Schwartz; D Weber; T Sullivan
Journal: Can J Psychiatry Date: 1990-10 Impact factor: 4.356

Review 2. Plasma level monitoring of antipsychotic drugs.

Authors: T B Cooper
Journal: Clin Pharmacokinet Date: 1978 Jan-Feb Impact factor: 6.447

3. Application of NONMEM to routine bioavailability data.

Authors: D A Graves; I Chang
Journal: J Pharmacokinet Biopharm Date: 1990-04

4. Letter: Estrogen effects on phenothiazine derivative blood levels.

Authors: M K el-Yousef; D H Manier
Journal: JAMA Date: 1974-05-13 Impact factor: 56.272

5. Effect of storage on the plasma concentration of chlorpromazine and six of its metabolites.

Authors: M Chetty; R Miller
Journal: Ther Drug Monit Date: 1991-07 Impact factor: 3.681

6. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report.

Authors: G L Stimmel; I R Falloon
Journal: J Clin Psychiatry Date: 1983-11 Impact factor: 4.384

7. Effect of antiparkinsonian medication on plasma levels of chlorpromazine.

Authors: G M Simpson; T B Cooper; N Bark; I Sud; J H Lee
Journal: Arch Gen Psychiatry Date: 1980-02

8. Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.

Authors: N M Graves; T M Ludden; G B Holmes; R H Fuerst; I E Leppik
Journal: Pharmacotherapy Date: 1989 Impact factor: 4.705

9. Chlorpromazine plasma level monitoring of schizophrenic patients.

Authors: E E Jones
Journal: J Clin Pharm Ther Date: 1988-12 Impact factor: 2.512

10. Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Authors: L Rivera-Calimlim; H Nasrallah; J Strauss; L Lasagna
Journal: Am J Psychiatry Date: 1976-06 Impact factor: 18.112

6 in total

Smoking and body weight influence the clearance of chlorpromazine.

1. Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics.

Review 2. Plasma level monitoring of antipsychotic drugs.

3. Application of NONMEM to routine bioavailability data.

4. Letter: Estrogen effects on phenothiazine derivative blood levels.

5. Effect of storage on the plasma concentration of chlorpromazine and six of its metabolites.

6. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report.

7. Effect of antiparkinsonian medication on plasma levels of chlorpromazine.

8. Pharmacokinetics of felbamate, a novel antiepileptic drug: application of mixed-effect modeling to clinical trials.

9. Chlorpromazine plasma level monitoring of schizophrenic patients.

10. Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Review 1. Drug interactions between herbal and prescription medicines.

Review 2. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.

Review 3. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective.

4. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia.

5. Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder.

Review 6. Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review.